Business Description
Enzymatica AB
NAICS : 325412
SIC : 2834
ISIN : SE0003943620
Description
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.46 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.49 | |||||
| Beneish M-Score | -3.11 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.4 | |||||
| 3-Year EBITDA Growth Rate | -89.1 | |||||
| 3-Year EPS without NRI Growth Rate | -49.4 | |||||
| 3-Year FCF Growth Rate | -32.3 | |||||
| 3-Year Book Growth Rate | -14.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.2 | |||||
| Quick Ratio | 0.84 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 225.92 | |||||
| Days Sales Outstanding | 75.78 | |||||
| Days Payable | 86.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -4.8 | |||||
| Shareholder Yield % | -2.58 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.59 | |||||
| Operating Margin % | -94.42 | |||||
| Net Margin % | -97.69 | |||||
| FCF Margin % | -80.58 | |||||
| ROE % | -48.91 | |||||
| ROA % | -33.78 | |||||
| ROIC % | -41.73 | |||||
| ROC (Joel Greenblatt) % | -259.48 | |||||
| ROCE % | -38.75 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.94 | |||||
| PB Ratio | 7.25 | |||||
| Price-to-Tangible-Book | 69.23 | |||||
| EV-to-EBIT | -12.52 | |||||
| EV-to-EBITDA | -12.52 | |||||
| EV-to-Revenue | 11.7 | |||||
| EV-to-FCF | -14.52 | |||||
| Price-to-Median-PS-Value | 1.17 | |||||
| Earnings Yield (Greenblatt) % | -7.99 | |||||
| FCF Yield % | -7 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enzymatica AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 50.904 | ||
| EPS (TTM) (kr) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (kr) | 0 | ||
| 20-Day SMA (kr) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (kr) | 7 - 15.4 | ||
| Shares Outstanding (Mil) | 24.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enzymatica AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enzymatica AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Enzymatica AB Frequently Asked Questions
What is Enzymatica AB(XSAT:ENZY)'s stock price today?
The current price of XSAT:ENZY is kr9.00. The 52 week high of XSAT:ENZY is kr15.40 and 52 week low is kr7.00.
When is next earnings date of Enzymatica AB(XSAT:ENZY)?
The next earnings date of Enzymatica AB(XSAT:ENZY) is 2024-04-25.
Does Enzymatica AB(XSAT:ENZY) pay dividends? If so, how much?
Enzymatica AB(XSAT:ENZY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers